Clinical trials: Biliary Cancer
Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
- Trial name
- NCT07020221
- Testing
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 616 people
- Sponsor
- Verastem, Inc.
Biliary Tract Neoplasms
Single-arm, Multicenter, Open-label Phase II Study of Vedotin for Injection in Second-line or Later Treatment of Advanced Biliary Tract Cancer
Malignant tumors of the biliary system are highly invasive and malignant with an increasing incidence rate. Comprehensive drug therapy is the main treatment for advanced biliary tract tumors, yet the current gemcitabine plus…
- Trial name
- NCT07890311
- Testing
- MRG003 (Becotatug Vedotin)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangmen Central Hospital
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers.
- Conditions
- Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06428409
- Testing
- Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Biliary Tract Cancer, Biliary Tract Neoplasms
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is no longer working.
- Conditions
- Biliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT07146646
- Testing
- Trifluridine/tipiracil, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Fluid Collections, Biliary Obstruction
EUS Procedures Using RIVOS™ EUS Access Device
This is a prospective study of patients undergoing EUS procedures using the RIVOS™ EUS access device.
- Conditions
- Pancreatic Fluid Collections, Biliary Obstruction, Pancreatic Duct Obstruction, Chronic Pancreatitis
- Trial name
- NCT07696572
- Testing
- EUS-guided intervention using the RIVOS™ EUS access device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Orlando Health, Inc.
Biliary Track Cancer
Histotripsy in Biliary Tract Cancer
The purpose of this pilot study is to examine the safety and feasibility of histotripsy in two cohorts of 12 patients each with Biliary Track Cancer (BTC), with a plan to expand to a larger multi-center study if both safety and…
- Trial name
- NCT07853690
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma
- Trial name
- NCT05564403
- Testing
- Binimetinib, Biopsy Procedure, Biospecimen Collection
- Where
- 207 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Biliary Stenosis
Hot AXIOS™ for Bile Duct Drainage in Malignant Stenosis
The study is designed to highlight the effectiveness of the Hot AXIOS™ stent when used in accordance with standard medical practice on the evolution of the quality of life of patients with malignant biliary stenosis requiring…
- Trial name
- RAINBOW (NCT06750146)
- Testing
- Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System
- Where
- 18 sites in France
- Volunteers
- 162 people
- Sponsor
- Boston Scientific Corporation
Thymoma, Stomach Neoplasms
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Background: Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. Mesothelioma accounts for 0.10% of deaths annually in the United States.
- Conditions
- Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma
- Trial name
- NCT01950572
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma, Bile Duct Neoplasm
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Background: Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts. People with CCA have few treatment options and poor survival. Researchers want to see if a new drug can stop or slow CCA growth.
- Conditions
- Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
- Trial name
- NCT04645160
- Testing
- Tivozanib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Biliary Tract Cancer
Blood Flow Restriction Exercise in Patients With Pancreatic, Biliary Tract, and Liver Cancer (PREV-Ex)
In patients with cancer, resistance training appears to be a safe and effective exercise modality to increase both lean muscle mass and strength, as well as attenuates cancer-related fatigue.
- Conditions
- Pancreatic Cancer, Biliary Tract Cancer, Liver Cancer
- Trial name
- PREV-Ex (NCT05044065)
- Testing
- Physical exercise
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 52 people
- Sponsor
- Karolinska Institutet
Biliary Cancer, Bile Duct Cancer
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Background: Biliary tract carcinoma (BTC) is cancer of the slender tubes that carry fluids in the liver. People with advanced BTC have few treatment options, and their survival rates are very low.
- Conditions
- Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
- Trial name
- NCT05849480
- Testing
- oxaliplatin, capecitabine, Keytruda
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Cancer
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.
- Trial name
- NCT06109779
- Testing
- Rilvegostomig, Capecitabine, Gemcitabine/Cisplatin
- Where
- 176 sites in United States, Australia and 19 more
- Volunteers
- 760 people
- Sponsor
- AstraZeneca
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Gastrointestinal Cancers, Frailty
Longitudinal Geriatric Vulnerability, Chemotherapy Toxicity, and Functional Outcomes in Older Adults With Gastrointestinal Cancer
Older adults with gastrointestinal cancers may be more likely to experience side effects from chemotherapy and difficulties with everyday activities. These problems are not always explained by age alone.
- Conditions
- Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly, Malnutrition Elderly
- Trial name
- VITAL-GI (NCT07184047)
- Testing
- Standard-of-Care Systemic Chemotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 132 people
- Sponsor
- Ankara Etlik City Hospital
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Cholangiocarcinoma, Hilar Cholangiocarcinoma
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
This is a phase II, single-arm, prospective clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy combining stereotactic body radiotherapy (SBRT), GP chemotherapy (gemcitabine and…
- Conditions
- Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT07030140
- Testing
- Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jinbo Yue
Biliary Tract Cancer (BTC)
Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer
After the standard first-line treatment, the treatment regimen was adjusted to a paclitaxel polymer micellar-based immunotherapy combination regimen
- Trial name
- PILOT-BTC (NCT07159204)
- Testing
- Paclitaxel polymer micelle immunocombination
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.